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Abstract 
 
 
Background: EC express and present MHC class I restricted peptide antigens 
and due to the exposed position may be targeted by antigen-specific CTL. We 
wished to explore the type of vascular injury that is mediated by peptide-
specific CTL in vivo when EC express the source protein from which the 
antigenic peptide is derived. Methods: We immunized mice that express E.coli 
?-galactosidase (LacZ) as an antigen specifically under the control of the 
thrombomodulin promoter, i.e. in vascular endothelial cells, with ?-gal(500-507) 
pulsed dendritic cells. The peptide specific CTL-response was assessed in 
splenocytes by intracellular cytokine staining after peptide incubation and 
histopathological tissue sections were scrutinized for CTL-mediated EC injury. 
Results: After subcutaneous immunization, on average 1% of the CD8+ 
splenocytes were ?-gal-peptide specific effector cells. Despite of successful 
immunization we were unable to detect antigen-specific endothelial injury in 
TM-LacZ mice. A GVHD-like chronic inflammatory, antigen-specific disease 
characterized clinically by mild wasting was induced in ROSA26-LacZ mice, 
which ubiquitously express LacZ. Accidentally we observed persistent lung 
inflammatory infiltrates in mice that received intravenous injections of 
splenocytes or dendritic cells. These perivascular granuloma-like lesions 
consisted of highly proliferating CD11c+ recipient cells and were not the result 
of DC trapping. Conclusions: Endothelial cells escape CTL-mediated 
apoptosis in vivo. Intravenous injection of splenocytes and dendritic cells or 
both, leads to a model of pulmonary granuloma formation and this may 
represent an early stage of vasculitis.  
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1.Introduction 
 
Vascular endothelial cells (EC) are important for the maintenance of vascular 
function. The spectrum of immune-mediated endothelial injury is broad. It can 
precipitate rapid multi-organ failure 7 or it can result in silent tissue remodeling 
such as seen in chronic graft versus host disease (GVHD) 8. Cytotoxic T 
lymphocytes (CTL) recognize antigen as MHC class I-peptide complexes 9. 
EC express MHC class I molecules and can therefore become targets of 
CD8+ CTL. EC are an exposed target tissue in the course of any immune 
response. When EC present cognate antigen that activates transmigrating 
effector CTL rapid EC death may result. However, the outcome of an 
interaction between effector CTL and EC can be manifold (Figure 1) ranging 
from ignorance to overt EC death. The aim of this thesis project was to 
investigate antigen-expressing EC as target cells for antigen-specific CTL in 
vivo, and assess the outcome of this interaction and describe the phenotype 
of CTL-mediated endothelial injury. 
 
 
1.1 Cytotoxic T cell-mediated immune responses 
Cytotoxic T lymphocytes (CTL) are one of the antigen-specific effector arms of 
the adaptive immune system 10. They were originally discovered as mediators 
of solid organ transplant rejection and GVHD but are physiologically important 
for immune defense against non-cytopathic intracellular microorganisms and 
tumors 11. The highly variable T cell receptor (TCR) of a CTL recognizes 
antigenic peptide bound to major histocompatibility complex class I receptor 
(MHC class I) 12. CTL are usually T lymphocytes that carry the co-receptor 
CD8. CD8 interacts with the MHC class I molecule and facilitates recruitment 
and activation of the tyrosine kinase Lck to the TCR complex. Lck 
phosphorylates CD3 and ?, two signaling components of the TCR. Efficient 
signal transduction through the TCR results in various response patterns 
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ranging from cytotoxic granule release to cytokine gene expression. The 
maturation and differentiation state of the CD8+ T cell determines the signal 
strength required for full T cell activation. MHC class I restricted antigens are 
either derived from endogenous 13 or intracellular proteins that are degraded 
by the proteasome in the cytoplasma 14. Cytoplasmic peptides allocated to the 
MHC class I pathway are transported by the transporter associated with 
antigen processing (TAP) 15 from the cytosol into the lumen of the 
endoplasmic reticulum (ER). Peptides are assembled with MHC class I 
molecules in a complex in presence of chaperones 16. Finally, peptide-MHC 
class I complexes are translocated to the surface of a target cell to be 
presented to the CTL 17,18. 
 
 
 
Figure 1. Potential outcome of an interaction between EC and an effector CTL.  
Effector CTLs interact with endothelial cells through their T-cell receptor (TCR??) and the 
major histocompatibility complex (MHC) class I molecule – peptide complexes on the 
endothelial cell surface. The outcome of such an interaction may be: a) EC apoptosis 
2,3
, b) 
CTL inactivation by anergy or deletion 
4
 or c) mutual ignorance 
5,6
. 
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Pro-T-lymphocytes arise from stem cells in the bone marrow and migrate to 
the thymus for maturation. The thymus is the primary lymphoid organ involved 
in T cell generation. During this process, the T cell precursors somatically 
rearrange gene segments of the ? and ? chains of the T-cell receptor (TCR). 
This process leads to the extraordinary diversity of the TCR that is required 
for meeting the challenges of antigen recognition. After leaving the thymus, 
each mature naïve T cell possesses a unique TCR dedicated for antigen 
recognition and a single co-receptor, either CD4 or CD8 for forming the 
interaction with MHC class II or I, repetitively. T cells are then homing to the 
secondary lymphoid organs, the tissue compartment where professional 
antigen presenting cells (e.g. dendritic cells) can further activate these cells to 
proliferate and differentiate into effector T lymphocytes. 
 
For the effective activation of naïve CD8 T cells (pre-CTL) into cytotoxic 
effector CTL, several concomitant signals are required. When a naïve CD8 T 
cell encounters antigen as a specific peptide-MHC I complex presented by 
APC, this interaction is further stabilized by the CD8 co-receptor. A second 
signal needs to be delivered through costimulatory ligands (e.g. CD80 and 
CD86) that are highly expressed on activated APC. These ligands bind to the 
costimulatory CD28 receptor, which is expressed on naïve CD8 T cells. The 
two signals through TCR and costimulatory molecules activating leads to 
cytokine synthesis and secretion, upregulation of the IL-2 receptor ?-chain 
(CD25) and promotes T cell proliferation and differentiation 19,20. Once 
activated, the CTL undergo clonal expansion with the help of T cell growth 
factors such as interleukin-2 (IL-2). IL-7 or IL-15 are differentiation factors and 
involved in homeostatic proliferation 21,22. Recent data also demonstrate an 
important role of IL-12, interferons (IFNs), IL-10 and TGF-? which are all 
critical to support T cell survival and growth at different stages of CTL 
differentiation 21.  
 
The degree of inflammation, precursor frequency, antigenic signal strength 
and duration determine the efficiency of pre-CTL differentiation 21,23-25. The 
majority of reactive effector CTL that emerge after clonal expansion are short-
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lived and undergo apoptosis after the task is accomplished, i.e. antigen-
bearing target cells are eliminated. Only a small number of antigen-
experienced cells survive for a long time as memory T cells. These memory T 
cells are subdivided into two populations on the basis of their migratory ability 
26: the so-called effector memory T cells migrate to peripheral tissues, 
whereas central memory T cells express a repertoire of homing molecules 
similar to that of naïve CD8 T cells and migrate to lymphoid organs. Upon re-
encounter with their cognate antigen, memory T cells can very efficiently 
respond by strong proliferation and undergo a rapid transition into effector 
CTL 27.   
 
Mature, differentiated effector CTL leave the secondary lymphoid organs and 
reach peripheral tissues to kill antigen-bearing cells within minutes to hours by 
at least three distinct pathways 28: Upon recognizing cognate antigen, CTL 
release perforin and granzymes from preformed granules. Perforin forms 
pores in the plasma membrane of target cells allowing granzymes to enter 
and cause cell death 29. Second, CTL express membrane-bound CD95L, and 
this executor molecule is upregulated on the cell surface after TCR activation. 
CD95L binds to Fas (CD95) on target cells and induces receptor-mediated 
apoptosis. The third pathway is soluble cytokine-mediated. Activated CTL 
synthesize and release cytokines, such as tumor necrosis factor-? (TNF-?). 
TNF-? itself binds to TNFR 1 and 2. The outcome of TNF-? acting on target 
cells depends on the cell type and cellular activation state. In vascular 
endothelial cells the TNF response pattern reaches from apoptosis to survival 
30. IFN?, a second cytokine produced by activated effector CTL upregulates 
expression of MHC class I and various adhesion molecules in target cells. 
IFN? and TNF-? act synergistically on vascular endothelial cells inducing a 
more than additional response of two signals 31. Enhanced presentation of 
endogenous peptides by MHC class I and upregulation of adhesion and 
costimulatory molecules favor engagement of CTL with target cells. Induced 
expression of Fas further increases susceptibility to target cell killing 32. Fully 
differentiated effector CTL are capable to kill antigen-presenting target cells in 
the absence of any costimulatory signals or co-receptors. 
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In the face of the fatal cytotoxic potential of fully differentiated effector CTL, it 
is crucial that these cells respond only to infected or transformed target cells 
but ignore self-peptides. This discrimination between self and non-self is 
maintained by a process called tolerance. Immunological tolerance is 
achieved by central and peripheral mechanisms. Central tolerance is 
established during development of pro-T cells in the thymus. During this 
process, immature T cells that recognize self-peptide-MHC complexes with 
high affinity are deleted by a process referred to as negative selection, 
whereas T cells that express TCR with low affinity for self-peptide-MHC 
ligands are positively selected 33. T cells that fail to bind thymic self-antigens 
are eliminated by neglect. Among the T cells that populate the peripheral 
lymphoid tissues are found cells that display strong reactivity to foreign 
antigens, but are tolerant towards self-antigens 34-36. Since many peripheral 
tissue-specific self-antigens are constitutively expressed in thymic epithelial 
cells (TECs), central tolerance protects even against tissue-specific peripheral 
antigens. This function depends on the expression of the autoimmune 
regulator (ARIE) gene 33,37. By similar mechanisms, stromal cells in secondary 
lymphoid organs can present tissue-specific antigens to T cells. Antigen 
presentation by lymph node stroma is sufficient to induce primary activation 
and subsequent tolerance among naïve CD8 T cells 38. 
 
Central tolerance mechanisms are not completely protective against self-
reactive lymphocytes. In fact, low avidity self-reactive T cells are normally 
present in peripheral blood of healthy donors 39 and can cause autoimmune 
disease 40. Therefore, different peripheral-tolerance mechanisms exist to 
eliminate, inactivate or suppress self-reactive CTL who survived central 
tolerance mechanisms in the thymus 41. Peripheral tolerance is either 
accomplished by peripheral deletion, by anergy or by ignorance 42. Activated 
DCs present self-antigen to naïve CD8+ T cells in peripheral tissues, and this 
process could provide an opportunity for autoreactive CD8 T cell activation. In 
the absence of toll-like receptor signals, DCs are quiescent and express low 
levels of costimulatory molecules 43. Lack of costimulation does not promote 
increased levels of antiapoptotic molecules, therefore leads to CTL death 44,45. 
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Anergy is an active process that is dependent upon the continuous presence 
of antigen, as the cells regain their ability to respond to antigen once they are 
allowed to rest in the absence of antigen 46. High doses of antigen persistently 
presented promote CD8 T cell anergy and low doses induce cell death. The 
persistent presence of self antigens leads finally to complete clonal deletion 
4,47,48. Self-reactive T cells may be unable to cause harm by simply ignoring 
self-antigen 42. Taken together, tolerance mechanisms normally prevent CTL 
attacking self-peptides presented on self-MHC class I molecules and only 
failure of all levels of tolerance leads to overt autoimmune disease.  
 
In summary, an efficient CTL-mediated immune response is initiated if a naïve 
or memory CTL recognizes specific peptide-MHC I complex on an activated 
professional APC. Under normal circumstances, central and peripheral 
tolerance mechanism control autoreactive CD8+ T cells and prevent CTL-
mediated autoimmune diseases. 
 
 
1.2 Endothelial cells as a target of immune mediated injury   
Vascular endothelial cells (EC) form the luminal, single-cell pavement of the 
blood vessel and heart that represents an interface between liquid blood on 
one and solid tissues on the other side. EC have crucial functions in organ 
homeostasis by prevention of blood coagulation, regulation of vascular 
diameter, tone and permeability and controlling cell recruitment. Vascular 
endothelium is an important checkpoint and amplifier of any immune 
response, be it antimicrobial, anti-transplant or anti-self 49. EC are in intimate 
contact with CTL under two different circumstances. First, when CTL circulate 
in blood they contact EC by passing through capillaries where the diameter is 
narrower than a T cell’s diameter. Second, transmigrating CTL leave the 
blood and enter the tissue by squeezing through the endothelial monolayer, 
thereby having tight cell-cell contact.  
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There are several potential interactions between EC presenting antigen and 
CD8+ T cells recognizing antigen. First, EC can activate memory CD8+ T cells 
to proliferate and differentiate into effector CTL both in vitro and in vivo 50-52.  
Second, EC can induce antigen-specific tolerance. Lung EC negatively 
regulate CD8 T cell function 53. Liver sinusoidal EC can induce CD8 T cell 
tolerance to soluble 54,55 or tumor-derived antigens 56. By another postulated 
mechanism, immunological ignorance, vascularized solid organ 
allotransplants were tolerized by the immune system in aly/aly mice, These 
mice lack secondary lymphoid organs, suggesting that endothelial antigen 
presentation was not sufficient to initiate an immune response. These 
experiments demonstrated on the other hand that the primary activation of 
efficient T cell responses mediating solid organ transplant rejection are 
dependent on an organized interaction between APC and CD8 T cells within 
secondary lymphoid tissues 6. Endothelial ignorance and a certain level of 
peripheral, antigen specific tolerance by crosspresentation has recently been 
described in a mouse model of endothelial cell specific and restricted antigen 
presentation 57. 
 
Third, another important interaction sets EC as possible targets of a CTL-
mediated immune response. Many microvascular EC, which are lining 
capillaries and venules express high level of MHC class I 58. Therefore they 
are an exposed target tissue in the course of CTL-mediated immune 
diseases. Effector T cells transmigrate through monolayers of vascular EC 
during their passage to peripheral tissues. If EC express and present cognate 
antigen that activates transmigrating effector CTL they may be recognized as 
target cells and this contact should result in rapid EC death 59. CTL-mediated 
EC injury can be caused by cytotoxic effector molecules such as 
perforin/granzyme B, Fas ligand or TNF-? 60. This project will focus on EC as 
targets of antigen-specific CTL.  
 
In an animal study 3, disseminated CD95-mediated endothelial cell apoptosis 
was observed in all organs after i.v. injection of Fas-ligating antibody or 
systemic transfer of allogeneic lymphocytes into recipient mice. When CD95L 
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knockout lymphocytes were used, no endothelial injury was observed. Two 
findings were intriguing in these early studies: although widespread 
endothelial apoptosis was observed by histopathological criteria, no organ 
dysfunction occurred. Further evidence of a discrepancy between extensive 
endothelial injury and lack of consequences was that the mice were relatively 
healthy and no fatalities were observed. Interestingly, there were signs of 
lymphocyte mediated EC apoptosis but no inflammatory infiltrates. These 
findings were confirmed in a second animal study performed by the same 
group of investigators, in a model of acute GVHD. Both EC apoptosis and 
GVHD were completely dependent on CD95-CD95L ligand interaction 2. Still, 
no disseminated microvascular coagulation, no multi-organ failure and no 
inflammatory infiltrates were observed.  
 
In summary, in their neuralgic position at the interface between blood and 
tissue, EC are involved in regulating several key physiological functions, both 
immune and non-immune. EC are positioned to come into contact with 
circulating and recirculating T cells. EC can activate memory T cells by 
presenting antigens, can induce the CD8 T cell tolerance and can be targets 
of an effector CTL-mediated immune response. 
 
 
1.3 Inflammatory infiltrates and organ injury 
Inflammation is the complex biological response of tissue to harmful stimuli. 
Pathologically, local inflammation is characterized by redness (rubor), 
hyperthermia (calor), swelling (tumor) and pain (dolor) and at least 3 of 4 of 
these phenomena involve EC. Inflammation is a protective attempt of the 
organism to remove injurious stimuli by innate and adaptive immune 
responses and initiates tissue repair 61. This response involves tissue 
microvessels, the immune system and parenchymal and stroma cells within 
the injured tissue. A fundamental event in the inflammatory reaction is the 
localized and restricted recruitment of blood leukocyte subsets to tissues 
through endothelial-dependent mechanisms 62. Mediators of inflammation can 
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activate EC by upregulating the expression of adhesion molecules, involved in 
leucocyte tethering and adhesion which precede both transmigration through 
the EC and recruitment to peripheral tissues 63. Among the various effector 
leucocytes are also differentiated effector CTL which transmigrate through EC 
into inflamed tissues in order to contribute to an efficient immune response 64.  
 
Vasculitis is a group of diseases with inflammation localized to the wall of 
blood vessel. Vasculitis can affect veins, arteries and capillaries. A hallmark of 
vasculitis is injury and destruction of the vessel wall. Systemic vasculitides 
have a predilection for certain organs, and interestingly, most of them involve 
lung and kidney. They can cause severe disability, such as in pulmonary-renal 
syndrome and even have a fatal course. Pulmonary vasculitis is a primary 
idiopathic vasculitis restricted to the lung. Wegener’s granulomatosis (WG), 
which belongs to the ANCA-positive vasculitides, affects small to medium-
sized vessels, including venules and arteries. WG is characterized by 
granulomatous inflammations, necrotizing vasculitis in the respiratory tract 
and glomerulonephritis. Microscopic polyangiitis (MPA) affects capillaries, 
venules or arteries, forming the focal, segmental necrotizing vasculitis and a 
mixed inflammatory infiltrates without granulomata. Pulmonary vasculitis can 
be primary immune complex-mediated, like Goodpasture’s syndrome, which 
also presents with acute renal failure due to rapidly progressive 
glomerulonephritis 65. Focussing on vascular EC as targets of CTL-mediated 
injury we hypothesized that the type of tissue injury that we would observe 
could resemble some form of pauci-immune vasculitis 66. 
 
 
1.4 Aims and approaches of the study 
In my project, I wished to focus on CD8 T cell mediated EC injury in vivo. In 
order to address this question I used a mouse model in which a protein 
antigen, E.coli ?-galactosidase, was expressed exclusively by EC. This would 
allow investigating CTL-mediated injury limited to EC. The MHC class I / H2kb 
restricted, immunodominant epitopes are well characterized and therefore I 
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could work with antigenic peptides both at the level of CTL induction and 
functional CTL characterization. Currently, a number of transgenic mouse 
lines are available that exhibit EC-restricted expression of E.coli ?-
galactosidase: von Willebrand Factor-LacZ mice 67 show transgene 
expression restricted to yolk sac and brain EC. Tie2-LacZ mice 68 uniformly 
express transgene in endothelial cells of all organs. In my project, I used TM-
LacZ mice 1 on a C57/B6 background. In this model, the ?-galactosidase gene 
is knocked in to be expressed under the control of the thrombomodulin (TM) 
promoter. Homozygous knock-in mice are embryonically lethal. Therefore, 
breeding was between heterozygous and wild type animals and 50% of 
offspring was heterozygous TM-LacZ and 50% wild type (wt). I found these 
mice to be well-suited to study EC–CD8 T cell interaction in vivo, because the 
internal control of antigen-positive versus antigen-negative EC existed in the 
same animal.  
 
In order to establish and investigate an anti-EC CTL response, my project 
addressed the following hypotheses: 
 
1. An anti-EC CTL-mediated autoimmune response can be elicited  
To induce strong sustained autoimmune response against peripheral 
EC-restricted self-antigen, repetitive injections of high doses of ?-
gal(500-507)- primed DC over a prolonged period were applied. This 
protocol was shown to break tolerance against vascular smooth muscle 
cell-restricted ?-galactosidase 69.  
 
2. An anti-EC CTL-mediated, mHA restricted alloimmune response can 
be elicited 
In order to induce ?-gal(500-507)-specific CTL, we performed bone 
marrow transplantation using wt mice as donors and TM-LacZ mice as 
recipients. This mimics MHC-matched transplantation across minor 
histocompatibility barriers. Under these conditions, ?-galactosidase 
represents a minor histocompatibility alloantigen.  
 
  21 
3. An anti-EC CTL-mediated immune response is observed by adoptive 
transfer of effector CTL 
To investigate the direct interaction between ?-gal(500-507)-specific 
effector CTL and EC, antigen-specific effector CTL were adoptively 
transferred to the TM-LacZ mice. It was recently shown that fully-
differentiated effector CTL cells were less effective for adoptive transfer 
in an anti-tumor immunotherapy model 70. Therefore we also 
transferred ?-gal(500-507)-primed splenocytes to the TM-LacZ mice in 
certain experiments.  
 
4. Toll-like receptor activation aggravates CTL-mediated EC injury  
Lang 71 showed that among the various of Toll-like receptor ligands, 
poly(I:C) was able to transform tissue infiltration by autoreactive CTL 
into overt autoimmune disease through upregulation of MHC class I 
expression by IFN?. Based on this observation, in selected 
experiment, mice were poly(I:C) treated. 
 
5.  Route of immunization affects the efficiency of anti-EC CTL-mediated 
immune response  
Labelling studies with radioactive tracer have demonstrated that there 
are significant differences in the distribution of DC that are 
administered by different routes 72,73. Cells injected intravenously (i.v.) 
were first collected in lung and then redistributed to the liver, spleen 
and bone marrow. Cells injected subcutaneously (s.c.) or intradermally 
(i.d.) can migrate to draining lymph nodes with varying efficiencies. We 
tested whether the route of DC administration is important for the 
outcome of immunization in vivo. Mice were immunized by i.v., s.c. and 
intraperitoneal (i.p). injection of ?-gal(500-507) peptide pulsed DC.  
 
6. During the study of EC as target of antigen-specific CTL, the 
systematic histological analysis of various organs (liver, lung, kidney 
and heart) for signs of immune mediated injury revealed an unexpected 
finding: consistent and reproducible lung inflammatory infiltrates (LII) of 
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variable severity without involvement of other organs after intravenous 
injection of immune cells. LII were not the result of an antigen-specific 
anti-EC CTL-mediated immune response as confirmed by control 
experiments. In order to further elucidate the pathogenesis of lung 
injury, I injected i.v. dendritic cells, splenocytes, bone marrow, purified 
CD4+ and CD8+ to the mice, either alone or in combination, and 
examined LII two weeks after injection.  
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2. Methods and Materials 
 
2.1 Mice  
All mice used in this study were kept under specific pathogen-free condition 
and in accordance with Swiss federal law. TM-LacZ mice (mouse strain 
(background C57BL/6-Ly5.2; H2kb) with a knock-in of E.coli ?-galactosidase 
gene under the control of the thrombomodulin promoter) have been described 
1 and were obtained from Hartmut Weiler-Güttler through the Animal 
Resource Center, Medical College of Wisconsin, Milwaukee WI, USA. TM-
LacZ mice were crossed with C57BL/6-Ly5.2 mice to keep heterozygous 
offspring. Genotyping of TM-LacZ mice was performed with the primer 
ATGGTGCCAATGAATCGT and GTGGTCGGCTTACGGCGGTG, yielding a 
513-bp PCR product (Figure 2). All experiments were carried out with age- 
(about 17 - 20 wk) and sex-matched animals, and littermates were used as 
wild type controls. For selected experiments, C57BL/6-Ly5.1 mice (H2kb) mice 
were used as a source of donor cells in order to determine the origin of 
infiltrating cells in lung inflammatory infiltrates or the degree of chimerism after 
bone marrow transplantation. Rosa26-LacZ mice 74 (background C57BL/6-
Ly5.2; H2kb), which express ?-galactosidase ubiquitously in all tissues of the 
developing embryo and in most tissues of the adult mouse, were used as 
control animals in certain experiments.  
 
 
 
 
  
B 
C 
A 
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Figure 2. Endothelial cell-specific ?-galactosidase expression in TM-LacZ mice.  
(A) ?-galactosidase is expressed under the control of the thrombomodulin (TM) promoter 1. 
(B) Genotyping offspring with ?-galactosidase PCR amplifying a 513bp fragment. (C) Whole-
mount X-gal staining in organs of TM-LacZ and C57BL/6 (wt) mouse. (D) Organ sections of 
TM-LacZ mice were stained for ?-galactosidase using X-gal as a substrate (blue). ?-
galactosidase positive cells are vascular endothelial cells. 
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2.2 Culture media 
LCM-10 medium, on the basis of RPMI-1640 (52400025), containing 10 % 
FCS (10270106), 2 mM L-glutamine (25030024), 100 U/ml penicillin and 100 
μg/ml streptomycin (15140122), 5 mM nonessential amino acids (11140035), 
5 mM sodium pyruvate (11360039) (all reagents from Invitrogen Life 
Technologies, Carlsbad, CA, USA) and 50 μM ?-mercaptoethanol (M7522, 
Sigma-Aldrich) was generally used for culturing mouse cells. LCM-2.5 
washing medium is based on RPMI-1640, containing 2.5 % FCS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 5 mM nonessential 
amino acids, 5 mM sodium pyruvate and 50 μM ?-mercaptoethanol.  
Cloning medium is LCM-10 medium supplemented with 2 ng/ml mIL-2.  
DC medium is LCM-10 medium supplemented with 10% of GM-CSF 
containing cell culture supernatant. For serum-free culture, Cellgro medium 75 
(2005, Cellgenix, Freiburg, Germany) supplemented with 100 U/ml penicillin, 
100 μg/ml streptomycin, 50 μM ?-mercaptoethanol, 10 ng/ml rmGM-CSF and 
10 ng/ml rmIL-4 was used. 
CTL assay medium is based on Medium-199 (31153026, Invitogen), 
containing 2% FCS, 5 mM HEPES (15630-056, Invitogen), 2 mM L-glutamine, 
100 U/ml penicillin, 100 μg/ml streptomycin. 
All single cell suspensions were washed with gPBS (1 ? Dulbecco’s 
phosphate-buffer saline containing 1 mM glucose) before injected into mice. 
 
 
2.3 Peptides, cytokines, chemicals and antibodies 
The H-2Kb-restricted ?-galactosidase peptide, ICPMYARV (?-gal(500-507)) was 
obtained from American Peptides (Sunnyvale, CA, USA). The chicken 
ovalbumin peptide, SIINFEKL (OVA(258-265)) was a gift from Ed Palmer 
(Department Biomedicine Basel, Switzerland). Peptides were dissolved in 
DMSO at 2 mM and stored at 4°C.  
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The following cytokines were used: recombinant mouse IL-2 (402-ML) was 
reconstituted at 20 μg/ml stock concentration; recombinant mouse TNF? 
(410-MT) at 1 μg/ml, recombinant mouse GM-CSF (415-ML/CF) at 100 μg/ml 
and recombinant mouse IL-4 (404-ML/CF) at 50 μg/ml. All recombinant 
cytokines were from R&D Systems. Stock solutions were stored in aliquots at 
-70°C.  
GM-CSF containing supernatant was generated from transgenically modified 
producer cell line XG3-GMCSF (gift from Ton Rolink, Department of 
Biomedicine, University of Basel). For continuous selection, these cells were 
cultured in 20 ml of LCM-10 medium in the presence of 1 mg/ml of geneticin 
(10131019, Invitrogen). After washing twice with LCM-2.5 washing medium, 5 
? 106 cells were cultured in 20 ml of LCM-10 medium for another two weeks.  
Then cells were spun down, supernatant was collected, filtered twice, and 
stored in aliquots at - 20°C.  
polyinosinic–polycytidylic acid potassium salt (poly(I:C), P9582) was 
reconstituted at 1 mg/ml and stored in aliquots at -70°C. Phorphol myristate 
acetate (PMA, P8139) was reconstituted at 10 μg/ml, ionomycin (10634) at 1 
mg/ml and brefeldin A (B6542) at 2 mg/ml. All chemicals were purchased from 
Sigma-Aldrich and stored in aliquots at -20°C. Calcein-AM (C1430, Molecular 
Probes, Invitrogen, Basel, Switzerland) was dissolved in DMSO at 5 mM and 
stored at -20°C. 5-Bromo-2'-deoxyuridine (BrdU, 16880, Sigma-Aldrich) was 
used for in vivo labeling of proliferating cells and was freshly prepared in 
drinking water at 0.8 mg/ml. 
 
Antibodies were used for FACS and immunohistochemistry. The source, 
specificity and conjugation are shown in Table 1.
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Table 1: Antibodies used for different experiments. 
 
Antigen Species Conjugate Supplier / donor Cat. No. Usage Titer
aHamster IgG FITC Miltenyi Biotec 130-092-962 FC 1:25
CD4 rat IgG PE Miltenyi Biotec 130-091-607 FC 1:25
CD4 rat IgG PE BD Pharmingen 553652 FC  1:100
rat IgG PE BD Pharmingen 553032 FC  1:100
rat IgG APC Miltenyi Biotec 130-091-606 FC 1:25
CD11c aHamster IgG FITC BD Pharmingen 557400 FC  1:200
CD11c aHamster IgG PE BD Pharmingen 557401 FC  1:100
CD45.1 mouse IgG FITC BD Pharmingen 553775 FC  1:200
CD45.1 mouse IgG PerCP eBioscience 45-0453-80 FC  1:100
CD45.2 mouse IgG FITC BD Pharmingen 553772 FC  1:400
CD45.2 mouse IgG APC BD Pharmingen 558702 FC  1:200
F4/80 rat IgG PE eBioscience 12-4801-82 FC  1:100
FasL aHamster IgG PE BD Pharmingen 555293 FC  1:100
H-2Kb mouse IgG FITC BD Pharmingen 553569 FC  1:200
I-Ab mouse IgG FITC BD Pharmingen 553551 FC  1:200
rat IgG FITC BD Pharmingen 554411 FC  1:200
BrdU mouse IgG FITC BD Pharmingen 347583 FC  1:10
- mouse IgG PE BD Pharmingen 555748 FC  5ul/tube
- mouse IgG FITC BD Pharmingen 55749 FC  5ul/tube
- mouse IgG APC BD Pharmingen 554681 FC  1:200
CD4 rat IgG purified Burkhard Ludewig YTS 191.1 IHC, FC  1:800
rat IgG purified Burkhard Ludewig YTS 169.4.2 IHC, FC  1:400
F4/80 rat IgG purified Regine Landmann - IHC, FC  1:300
CD11c aHamster IgG Bio BD Pharmingen 553800 IHC, FC  1:200
CD45.1 mouse IgG Bio BD Pharmingen 553774 IHC  1:200
CD45.2 mouse IgG Bio BD Pharmingen 553771 IHC  1:200
BrdU rat IgG purified Abcam ab6326 IHC  1:200
- rat IgG purified AbD Serotec mca1125 IHC, FC  1:200-800
- aHamster IgG Bio BD Pharmingen 553952 IHC, FC  1:200
- mouse IgG biotin BD Pharmingen 33812x IHC, FC  1:200
rat IgG goat antiserum purified Caltag Laboratories R40000 IHC  1:500
goat IgG donkey antiserum AP Jackson 705-055-147 IHC  1:2500
rat IgG donkey antiserum HRP Jakson 712-035-153 IHC  1:200
rat IgG donkey antiserum Alexa 488 Molecular Probes A21208 FC  1:400
- Steptavidin Cy2 Jackson 016-220-084 FC  1:400  
 
* FC: flow cytometry 
   IHC: immunohistochemistry 
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2.4 Isolation of cells from mouse organs 
 
2.4.1 Bone marrow  
Mice were sacrificed by cervical dislocation and the hind limbs were removed. 
Bone marrow was flushed out of dissected hind limb bones into LCM-10 
medium. The tissue was passed through a 40 μm nylon mesh (S31109279, 
Sefar) in order to obtain single cell suspensions. In certain experiments, 
erythrocytes were depleted by incubating the cells for two minutes in ice-cold 
ammonium chloride solution (see above 2.4.3). The total yield from the four 
leg bones of a 8- to 12-week-old C57BL/6 mouse was 3-5 ? 107 cells.  
  
 
2.4.2 Splenocytes  
Mice were sacrificed by cervical dislocation and the spleen was removed. 
Splenocytes were squeezed and filtered through a 70 μm nylon mesh (3053-
0201-10000, Sefar, Heiden, Switzerland) in order to prepare single cell 
suspensions. In certain experiment, erythrocytes were depleted by incubating 
the cells for two minutes with ice cold ammonium chloride solution (0.02 M 
Tris-HCl, 0.14 M NH4Cl, pH7.2). The total yield from the spleen of a C57BL/6 
mouse was about 108 cells.  
 
 
2.4.3 Peripheral blood mononuclear cell (PBMC) collection 
200 μl of blood was collected from the tail artery in a glass tube (12 ? 75mm, 
2787/6, DURAN, Germany) containing heparin (final concentration 500 U/ml, 
B. Braun Medical AG, Emmenbrücke, Switzerland). 2 ml of PBS was added, 
mixed and the diluted blood was layered over 2ml Ficoll-PaqueTM Plus (17-
1440-02, GE Healthcare Bio-Sciences AB, Sweden). Blood was spun at 2400 
rpm for 30 minutes at RT. After carefully removing the diluted plasma, PBMC 
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were harvested and washed in 3ml PBS (1400 rpm for 10 minutes). The 
PBMC pellet was then used for further experiments. About 2 ? 106cells /ml of 
peripheral blood was obtained.  
 
 
2.4.4 Purified CD4 and CD8 cells from spleen 
Erythrocyte-depleted splenocytes were washed two times with AutoMACS 
buffer (PBS, pH7.2, supplemented with 0.5% FCS and 2mM EDTA) and 
filtered through a 40 μm strainer. CD4+ and CD8+ populations were purified by 
negative selection using the mouse CD4+ T cell isolation kit (130-090-860) 
and mouse CD8?+ T cell isolation kit (130-090-859, Miltenyi Biotec Inc., 
Auburn, CA, USA), according to the manufacture’s instruction. Cell purity of > 
80% for all populations was confirmed by flow cytometry (Figure 3). Purified 
lymphocytes were then transferred intravenously into TM-LacZ mice. About 
1.5 ? 106 CD4+ and 106 CD8+ cells / 107 splenocytes were obtained. 
Figure 3. Phenotypical characterization of total splenocytes and purified lymphocyte 
populations.  
Generally, unfractionated splenocytes were used for adoptive transfer. For selected 
experiments, CD4
+ 
and CD8
+
 populations were purified from total splenocytes by using the 
mouse CD4
+ 
and CD8?+ T cell isolation kit. Cell composition was detected by FACS stained 
with fluorescently labelled (either FITC, PE or APC) anti-CD4, anti-CD8?, anti-CD3, anti-
CD19, anti-F4/80 and anti-CD11c mAbs. Gray line is isotype control, black line is 
Isotype control  unpurified splenocytes  purified CD4+  Purified CD8+
S
S
C
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unfractionated splenocytes, blue line is purified CD4 population and red line is purified CD8 
cell population. 
 
 
2.5 Bone-marrow derived dendritic cells (DC)  
Bone marrow derived DC were generated as described 76. The BM single cell 
suspensions were washed once with LCM-10 medium, and 0.5 ? 106 cells 
/cm2 were plated in DC medium. After 3 days of culture, 80% of culture 
supernatant was carefully replaced by fresh medium. For serum-free culture, 
Cellgro medium was used. After 6 days in culture, the resulting bone marrow-
derived DC population showed that more than 70% of the cells were CD11c+ 
and showed strong expression of MHC class I and II antigens (Figure 4).  
Figure 4. Phenotypical characterization of bone marrow-derived DC.  
Bone marrow (BM) cells were cultured in GM-CSF conditioned medium. After 6 to 8 days, 
non-adherent cells were collected and analyzed by FACS using fluorescently labelled mouse 
antibodies against CD11c, MHC I (H2k
b
), MHC II and CD8?. (A) BM cells. (B) Cultured DC on 
day 7. 
 
 
2.6 Immunization of mice 
After 6 to 8 days in culture, non-adherent C57BL/6 bone-marrow derived DC 
were collected, suspended at 5 ? 106 cells/ml and pulsed for 60 minutes at 
 
 
  31 
37°C in DC medium containing 10-5 M ?-gal(500-507) or OVA(258-265), 
respectively. After washing the cells three times with gPBS, 5 ? 105 DC in 
0.25ml gPBS were injected intravenously into the tail vein (i.v.), 
subcutaneously in the neck (s.c.) or intraperitoneally (i.p.). Unless otherwise 
indicated, immunization with peptide pulsed DC was repeated three times on 
consecutive days.  
 
 
2.7 In vivo primed, peptide-specific splenocytes 
Seven days after peptide-pulsed DC immunization, in vivo primed splenocytes 
were obtained. These cells were either used for adoptive transfer or for the 
generation of peptide-specific CTL lines. The fraction of peptide specific CD8+ 
cells was determined by ICS (Figure 8). 
 
 
2.7.1 Splenocytes adoptive transfer 
For adoptive transfer of DC/?-gal(500-507) primed splenocytes, erythrocytes 
were depleted by incubating the splenocytes for two minutes with ammonium 
chloride solution. The cells were then washed three times with gPBS, and 25 
? 106 cells in 0.5 ml gPBS were injected intravenously on day 0. In addition, 
the mice were immunized with ?-gal(500-507) pulsed DC on day 1, 2 and 3 as 
described 76. In selected experiments, mice were treated with 200 μg poly(I:C) 
i.p., a ligand for TLR3, one day before splenocytes adoptive transfer 71.  
 
 
2.7.2 Generation of peptide-specific effector CTL 
Seven days after DCs/?-gal(500-507) or DC/OVA(258-265) immunization, C57BL/6 
mice splenocytes were plated at 5 ? 106 cells/ml in a 24-well plate in 1 ml 
LCM-10 medium and 5 ? 106 cells/ml ?-gal(500-507) or OVA(258-265)  peptide 
pulsed splenocytes as feeder cells were added. Every 10 days, about 3 ? 106 
  32 
cultured responder were restimulated with 6 ? 106 peptide-pulsed, irradiated 
C57BL/6 splenocytes in cloning medium. The total cell number per well did 
not exceed 107. After 4 – 5 weeks, the effector CTL were phenotyped by 
FACS for CD8 expression (Figure 5A), and were tested functionally for 
peptide-specific lysis in a calcein-release cytotoxicity assay (Figure 5B). When 
the effector CTL were > 80% CD8 positive, and demonstrated peptide specific 
lysis > 70% at E/T ratio of 10:1, they were used for i.v. adoptive transfer into 
recipient mice.  
 
 
   ?-gal(500-507)     OVA(258-268) 
  
Figure 5. Phenotypical and functional characterization of peptide-specific effector CTL 
expanded in vitro.  
Primed splenocytes harvested seven days after immunization with ?-gal(500-507) or OVA(258-265) 
peptide-pulsed DC, respectively. They were cultured in vitro in the presence of IL-2 and 
restimulated every 10 days with ?-gal(500-507) or OVA(258-265) peptide pulsed, irradiated wt 
splenocytes for 5 weeks. (A) All effector CTL lines were > 80% CD8 positive (black line). Gray 
shade is isotype control. (B) Peptide specific cytotoxic activity of CTL lines was tested in a 
calcein-release cytotoxicity assay. The close squares indicate peptide-pulsed target cells, and 
the open squares indicate non-pulsed target cells.  
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2.8 Bone marrow transplantation 
Recipient mice were lethally irradiated with 11Gy at fractionated doses (6Gy 
and 5Gy with 4 hours interval). Within 24 hours after whole body irradiation of 
recipients, donor mice were killed, bone marrow was flushed from femurs and 
tibias, erythrocytes were depleted and single cell suspensions were prepared 
in gPBS. Recipient mice then received 107 bone marrow cells in 0.5 ml gPBS 
via tail vein injection. Survival and the degree of clinical GVHD after BMT was 
monitored daily, using a scoring system that sums changes in six parameters: 
weight loss, posture, activity, fur texture, skin integrity and diarrhea, as 
described 77,78. Animals were sacrificed when they lost more than 10% of their 
original body mass. Chimeric mice were maintained on water containing 
sulfadoxin and trimethoprin as antibiotics (Mepha Pharma AG, Basel, 
Switzerland) for 10 days post-transplant. Mice were used for experiments 8 to 
10 weeks after bone marrow reconstitution.  To check chimerism of the 
recipient, C57BL/6-Ly5.1 bone marrow was transplanted into Ly5.2 mice, or 
C57BL/6 BM into Rosa26-LacZ mice. Recipient mice were bled on day 35 and 
60 after BMT. PBMC were stained with anti-CD45.1 and CD45.2 mAbs 
respectively. Alternatively, ?-galactosidase activity was detected with 
fluorescein di-D-galactopyranoside (FDG) as a substrate (see below 2.16.2) 
and leukocyte reconstitution was checked in FACS (Figure 6A, 6B). Blood 
smears were used for differential blood counts (normal range of cell 
component of C57BL/6: neutrophils are 3.7-21%, lymphocytes are 68-92%, 
monocytes are 0.2-3%) (Figure 6C). 
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Figure 6. Blood reconstitution and donor chimerism after BMT.  
(A) C57BL/6-Ly5.1 BM was transplanted into C57BL/6-Ly5.2 recipient. After eight weeks, 
chimerism was tested by FACS in mouse PBMC. PBMC were stained with anti-CD45.1 (black 
line) and CD45.2 (red line) mAbs. Gray shade is isotype control (B) C57BL/6 (wt) BM was 
transplanted into Rosa26-LacZ (Rosa) recipient. After eight weeks, chimerism was tested by 
FACS in mouse PBMC. PBMC were stained with FDG as a substrate of ?-galactosidase (see 
methods). Black line is C57BL/6 mouse PBMC, green line is Rosa26-LacZ mouse PBMC, red 
line is chimera mouse PBMC (wt ? Rosa). (C) Completed leukocyte reconstitution in the 
peripheral blood eight weeks after BMT.  
 
 
2.9 Cell proliferation assay  
 
2.9.1 in vivo BrdU labeling 
In order to determine proliferation rate of lung inflammatory infiltrates, BrdU 
was administrated in drinking water (0.8 mg/ml) for 7 days before sacrifice the 
animals 79. BrdU-containing drinking water (light free) was made up fresh and 
changed daily.  
 
 
2.9.2 in situ tissue staining for proliferating cells 
The recipient mice were sacrificed at indicated time point. Cryosections of 10 
μm thickness were fixed with 4% paraformaldehyde in PBS at RT and washed 
twice with 1? PBS, incubated with 1N HCl at 37°C for 30 minutes. Then 
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quenched with methanol containing 0.3% of fresh H2O2, blocked with 1% 
FCS, 2% BSA, 0.1% Tween-20 in PBS for 30 minutes. Anti-BrdU antibody 
was incubated in PBS containing 1% FCS, 1% BSA, 10% DNAse buffer and 
DNAse (50 units/ml, M610A, Promega) for 2 hours, followed by goat anti-
donkey HRP and visualized by DAB (K3468, DAKO North America Inc., 
Carpinteria, CA, USA). The percentage of BrdU+ cells was calculated as: 
BrdU stained positive nuclei in the lesion area / total nuclei in same area ? 
100 (Figure 24A). 
 
 
2.10 Measurement of IFN? serum levels 
In order to confirm biological activity of poly(I:C) treatment we measured serum IFN? levels 
after the i.p. injection of 200 μg poly(I:C). 1, 6 and 24 hours after poly(I:C) treatment, 20 to 30 
μl of blood was obtained into a 0.5 ml Eppendorf tube from the mouse tail vein. Whole blood 
was kept for 10 minutes at RT to allow blood clotting, then 30 minutes at 4°C. The clotted 
blood was centrifuged at 2500 g for 20 minutes at 4°C, the supernatant transferred into a new 
tube and spun again at 1500 g for 10 minutes. The final supernatant was clear serum, stored 
in aliquots at -70°C before use. Serum was diluted 1:15 with dilution buffer and IFN? 
concentration determined with the mouse interferon alpha ELISA kit (42100-1, PBL 
Biomedical Laboratories, Piscataway, NJ, USA) according to the manufacturer’s instruction 
(Figure 7).  
 
           
 
Figure 7. Biological effect of poly(I:C) treatment as measured by IFN?  plasma levels. 
Mice were treated with poly(I:C) or PBS i.p. and blood was drawn from tail vein after 1, 6 and 
24 hours. IFN? level was determined in the serum by ELISA (±SEM, n=4 in each group). 
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2.11 Leukocyte surface phenotyping 
Generally, all FACS staining procedures were carried out at 4°C. 105 
cells/tube were washed once with 1% BSA-PBS and incubated with the 
respective conjugated antibodies for 30 min at 4°C. Cells were washed again, 
fixed in 2% paraformaldehyde in PBS and analyzed on a flow cytometry. For 
each quantitative analysis a cumulative number of 104 cells were collected in 
the live cell gate as defined by the typical pattern in the forward (FSC) and 
sideward scatter (SSC) display. The acquired fluorescence intensity data 
were further analyzed with BD CellQuestTM Pro software (Becton Dickinson). 
For unconjugated or biotinylated primary antibodies, Alexa Fluor? 488-
conjugated donkey-anti-rat IgG or CyTM2-conjugated streptavidin was used as 
a secondary antibody. 
 
 
2.12 Intracellular IFN?  staining for the detection of peptide 
specific CD8 T cells 
105 splenocytes were resuspened in 200 μl of LCM-10 medium containing 20 
μg/ml brefeldin A and 2 ng/ml recombinant mouse IL-2. To activate peptide 
specific CD8 T lymphocytes, cells were incubated for 5 hours at 37°C in the 
presence of 10-5 M of ?-gal(500-507) or OVA(258-265) peptide, respectively. As a 
positive control, cells were treated by PMA (final concentration, 10 ng/ml) and 
ionomycin (final concentration, 0.5 μg/ml). After T cell activation, the cells 
were washed and stained for 30min at 4°C with anti-mouse CD8?-PE Ab. 
Then the cells were washed twice with 1% BSA-PBS, fixed in 4% 
paraformaldehyde-PBS for 10 min, permeabilized with 0.1% saponin, 1% BSA 
in PBS for 10 min, and blocked with 1% FCS for 10 min. After washing twice, 
anti-mouse IFN?-FITC Ab was added for 30 min at 4°C.  The fraction of IFN? 
positive CD8 T cells was determined by FACS (FACS Calibur flow cytometer, 
BD Biosciences, San Jose, CA, USA). The percent age of peptide specific 
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CD8 T cells was calculated as (stimulated IFN? + CD8+ cells/ total CD8+ cells ? 
100) – (non-stimulated IFN? + CD8+ cells/ total CD8+ cells ? 100) (Figure 8). 
 
 
Figure 8. Quantification of peptide-specific CD8 positive splenocytes with ICS. 
After immunization with peptide-pulsed DC, wt mice splenocytes were isolated and activated 
for 5 hours with or without peptide or with PMA (10 ng/ml) and ionomycin (0.5 μg/ml) as 
positive controls. The percent age of peptide specific CD8 T cells was calculated as: % IFN? + 
CD8
+
 cells = 2.1 - 0.4 = 1.7%. 
 
 
2.13 Calcein release-based cytotoxicity assay 
Target cell lysis was assessed in vitro by a calcein release assay as 
described 50. Briefly, EL-4 cells (gift from Ton Rolink), a H2kb positive 
thymoma cell line used as targets were loaded for 30 min at 37°C with 20 μM 
calcein-AM in HBSS, washed with LCM-10 medium, and pulsed with indicated 
peptide (10-5 M) for 1 hour in RPMI complete medium at 37°C. After washing 
twice with CTL assay medium, EL-4 cells were counted and transferred to 96-
well, round-bottom plate at 104 cells/well. Peptide specific CTL were washed 
with CTL assay medium, counted and added to the calcein-loaded target cells 
(final volume, 200 μl/well) at titrated cell numbers resulting in decreasing 
Effector : Target ratios. EL-4 cells without peptide served as controls to 
determine non-specific cell lysis. Spontaneous release (SR) of calcein from 
EL-4 cells was determined by adding assay medium; maximum release (MR) 
was obtained in the presence of detergent by the addition of lysis buffer (50 
mM sodium borate in 0.1% Triton X-100 (both from Sigma-Aldrich), pH 9.0). 
After 2 hours, 75 μl supernatant was carefully removed and transferred to a 
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96-well, flat bottom plate. Released calcein was measured in a fluorescence 
multiwell plate reader (SpectraMax GeminiXS, Molecular Devices; excitation 
wavelength, 485 nm; emission wavelength, 538 nm). The percent specific 
lysis was calculated as (sample release – SR)/(MR – SR) ? 100. SR was < 
20% in all experiments (Figure 5B). 
 
 
2.14 Necropsy and organ embedding  
Mice were intraperitoneally euthanized with 30 mg/kg of pentobarbital.  
Before asystole, 200μl blood was collected from the left ventricle in heparin 
treated polypropylene tube (365966, BD MicrotainerTM tube) for the isolation 
of plasma. When used for intracellular cytokine staining or FACS, spleen, 
lymph node and bone marrow were collected. The mice were perfused with 
15 ml of PBS (37°C) followed by 30 ml of PIPES-buffered paraformaldehyde 
(0.1 M PIPES (pH 6.9), 2 mM MgCl2, 2% paraformaldehyde, and 1.25 mM 
EGTA). Subsequently, organs were removed and incubated in PIPES-
buffered paraformaldehyde for 2 hours, rinsed twice in PBS and equilibrated 
in 30% sucrose-PBS (wt/vol.) overnight. Tissues were embedded in OCT 
compound (4583, Tissue-Tek, Medite, Burgdorf, Germany) and snap frozen at 
-50°C. Frozen samples were stored at -70°C until further use. 10 μm tissue 
sections were cut with a cryotome (HM560, Microm International GmbH, 
Germany) onto Superfrost? plus glass slides (J1800AMNZ, Thermo Scientific, 
Menzel GmbH & Co. KG, Braunschweig, Germany). Sections were air dried 
for 30 minutes and either stained immediately or stored at -70°C until further 
use. 
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2.15 Histology and immunohistochemistry 
 
2.15.1 Hematoxylin-eosin (H&E) staining 
OCT was removed from tissue and tissue was rehydrated through graded 
ethanol: 100%, 95%, 75% and 50%, then washed with tap water. Slides were 
incubated with hematoxylin for 1 minute at RT, washed with tap water and 
warm water, then incubated with eosin for 30 second at RT. After washing 
with tap water, slides were dehydrated through graded ethanol: 50%, 75%, 
95% and 100% and mounted in Pertex (41-4010-00, Medite). Lung 
inflammation was quantified according to a semiquantitative score: 0 = no 
inflammatory infiltrates, 1 = mild perivascular inflammatory infiltrates, 2 = 
severe vascular and perivascular inflammatory infiltrates (Figure 9). All slides 
were coded and evaluated independently by two observers, one of which was 
blinded for the experimental conditions (BCB, XW). Generally, agreement 
between the two readers was >95%.  
 
 
Figure 9. Assessment of lung injury by a semiquantitative histopathological score.  
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Murine lungs were perfused, fixed and embedded in OCT. 10μm thick cryosections were 
stained with hematoxylin/eosin (H&E). (A) score 0 = no inflammatory infiltrates (B) score 1= 
mild perivascular inflammatory infiltrates and vasculitis (C) score 2 = severe perivascular 
inflammatory infiltrates and vasculitis, giant cell formation. The black stars show bronchi, 
black arrows show blood vessels and black arrowheads show giant cells. 
 
2.15.2 Immunohistochemistry  (IHC) 
To further characterize the cellular composition of the inflammatory infiltrates, 
immunohistochemistry was performed. Frozen tissue sections were fixed in 
acetone for 10 minutes, and non-specific binding sites were blocked for 30 
minutes with PBS containing 1% FCS, 2% BSA and 0.1% Tween-20. Sections 
were incubated with the first antibodies specific for CD4 (clone YTS191.1), 
CD8 (clone YTS169.4.2) (both gift from Burkhard Ludewig, Kantonsspital St. 
Gallen) or inflammatory macrophages (F4/80, gift from Regine Landmann, 
Department of Biomedicine, Basel) followed by goat anti-rat IgG. Finally, 
alkaline phosphatase-labeled donkey anti-goat IgG was added. The third 
enzyme conjugated antibody was diluted in Tris-HCl (0.1 M, pH 7.4) 
containing 5% normal mouse serum. Alkaline phosphatase was visualized by 
using AS-BI phosphate/New Fuchsin (SK-5100, Vector Laboratories, Inc., 
Burlingame, CA, USA). Endogenous alkaline phosphatase was blocked by 
Levamisole solution (SP-5000, Vector). Tissue staining with biotinylated anti-
CD11c, biotinylated anti-CD45.2 or biotinylated anti-CD45.1 was visualized by 
avidin-biotin-enzyme complex (PK-6100, Vector) and DAB. To block 
endogenous peroxidase, methanol containing 0.3% of H2O2 was used. Rat 
IgG2b, biotinylated Armenian hamster IgG1 and biotinylated mouse IgG were 
used as isotype controls at the same concentration as the first antibodies. 
Normally, antibodies were prepared in PBS containing 1% FCS and 1% BSA. 
Between the steps, slides were washed with PBS containing 0.1% Tween-20. 
All sections were counterstained with hematoxylin, dehydrated through 
graded ethanol: 50%, 75%, 95% and 100% and mounted in Pertex. Images 
were acquired using an OLYMPUS BX61 microscope equipped with 
ColorView and F-View cameras. Digital images were processed using 
Imaging software Cell^P (OLYMPUS Imaging Europa GmbH, Hamburg, 
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Germany) and Adobe Photoshop. The percentage of positive cells / total cells 
in area was calculated as: positive stained cells in lesion area / total cells in 
lesion area ? 100 (Figure 20D, 24C, 24D). 
 
 
2.16 ?-Galactosidase detection 
 
2.16.1 in situ tissue staining 
X-gal (V394A, Promega, Madison, WI, USA) was used as a substrate for ?-
galactosidase to detect enzyme expression in vascular endothelial cells as 
described 1. In brief, the frozen tissue sections were allowed to air dry, were 
postfixed with 2% paraformaldehyde in PBS for 10 minutes at RT. Then they 
were washed twice with PBS. Slides were incubated for 8-16 hours at 37°C in 
PBS (pH 7.4) containing NP-40 (0.02%), SDS (0.01%), MgCl2 (2 mM), 10 mM 
K3Fe(CN)6 and 10 mM K4Fe(CN)6 along with chromogenic ?-galactosidase 
substrate X-gal (1 mg/mL). Stained sections were rinsed with PBS and tap 
water, counterstained with Eosin, and dehydrated through graded ethanol: 
50%, 75%, 95% and 100% and mounted in Pertex (Figure 2). Whole mount 
staining of perfusion-fixed organs of tissue fragments was performed by 
incubation with X-gal overnight as described above. The frequency of X-gal 
stained blood vessels was calculated as: number of positive stained blood 
vessels in inflammatory infiltrates of whole lung area / all vessels involved in 
inflammatory infiltrates of whole lung area ? 100 (Figure 25D). 
 
 
2.16.2 ?-gal activity detected by FACS  
Single cell suspension of splenocytes, PBMC, lymph node and bone marrow 
cells (3 ? 105 cells / tube) were washed once with 1% BSA-PBS. Cells were 
then resuspended in 25 μl of 1% BSA-PBS and incubated for hypotonic 
loading with 25 μl of FDG (diluted 1:10, F1179, LUBIO) at 37°C for 30 
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minutes, returned to isotonicity at 4°C by adding 500 μl of ice-cold 1% BSA-
PBS, and stained with antibodies for specific surface proteins as described 74. 
For antibody staining of cells ‘‘loaded’’ with FDG, the cells were kept at 4°C at 
all steps in the staining procedure, including centrifugation in prechilled rotors 
and adapters. Antibody stains and the staining mediums used in the 
procedure also were kept on ice throughout the duration of the procedure.  
To exclude dead cells, propidium iodide  (PI, 5 μg/ml, 70335, Sigma-Fluka, 
Buchs, Switzerland) was used prior to data acquisition (Figure 5B). Cells were 
generally analyzed without fixation. 
 
 
2.17 Statistical data analysis 
To compare means of different groups, the Mann-Whitney U test was used. p 
values < 0.05 were considered to indicate a statistically significant difference 
between groups. Value of p representation: < 0.05 is represented by one 
asterisk; < 0.01 by two asterisk; < 0.001 by three asterisk Statistical data 
analysis was performed using SPSS 13 version for Mac OS X (SPSS Inc., 
Chicago, IL, USA). Unless indicated otherwise, mean ± SEM are shown. 
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3. Results 
 
 
3.1 Antigen – presentation by vascular endothelium: its role 
for CTL – mediated vascular injury 
 
3.1.1 Endothelial ?-galactosidase as an autoantigen 
In this study, TM-LacZ mice with beta-galactosidase (?-gal) expression 
confined to the vascular endothelium were used to study the interaction of 
CTL with EC. For TM-LacZ mice, ?-galactosidase is an autoantigen. In order 
to test the level of tolerance, the TM-LacZ mice were immunized repetitively 
i.v. with ?-gal(500-507)-pulsed DC 54 and the peptide-specific CTL response was 
determined two weeks later (Figure 10A). The intracellular IFN-? production 
by CD8 T cells upon in vitro stimulation with or without ?-gal(500-507) peptide 
was examined in splenocytes. There were no peptide specific CD8 T cells 
detectable in immunized TM-LacZ mice, under conditions, under which wt 
mice developed a strong immune response against ?-gal(500-507) (Figure 10B, 
10D). When mice were immunized with OVA(258-265)-pulsed DC,  no 
difference in the differentiation expansion of OVA-specific CD8 T cells was 
observed between wt and TM-LacZ mice. As a general sign of health, body 
weight of the mice was assessed. No significant weight change occurred 
during the course of the experiment (Figure 10C). There was no tissue injury 
detectable, in particular no vascular injury, in TM-LacZ mice. 
 
      
 
 
A 
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Figure 10. i.v. immunization of TM-LacZ mice with ? -gal(500-507)-pulsed DC. 
(A) Outline of the experimental design: TM-LacZ and wt mice were immunized with 5 ? 105 ?-
gal(500-507) or OVA(258-265) peptide pulsed bone-marrow derived DC, repetitively. (B) Two weeks 
after immunization, splenocytes from immunized mice were tested for peptide-specific CD8
+
 T 
cells by intracellular production of IFN? upon in vitro stimulation with or without ?-gal(500-507) or 
OVA(258-265) peptide. Values represent mean (± SEM of three independent experiments with 
similar outcome). (NS = not significant). (C) Changes in the body weight of mice in 
representative groups (pooled data) within two weeks, calculated as follows: ? body weight 
(% of total) = (weight (day 14) – weight (day 0)) / weight (day 0) ? 100. Shown is mean ± 
SEM. (D) Intracellular cytokine staining of individual mice was pooled from all experiments. 
Red lines represent median values. 
 
 
NS NS 
recipient 
DC 
experiments 
wt 
 
wt 
 
LacZ 
 
LacZ 
 
_________   _________ 
  ? -gal       OVA  
    3          1 
*** 
%
 I
F
N
?+
 C
D
8
+
 
?
 b
o
d
y
 w
e
ig
h
t 
 
 
(%
 o
f 
to
ta
l)
 
recipient 
DC 
 
wt 
 
wt 
 
LacZ 
 
LacZ 
 
________  ________ 
  ? -gal     OVA   
recipient 
DC 
wt 
 
wt 
 
LacZ 
 
LacZ 
 
_________   _________ 
  ? -gal        OVA   
*** 
%
 I
F
N
?+
 C
D
8
+
 
NS 
B 
D 
C 
  45 
3.1.2 Endothelial ?-galactosidase as a minor histocompatibility 
antigen  
In order to mimic vascular disease as observed during GVHD after MHC-
matched bone marrow transplantation, we performed bone marrow 
transplantation with wt mice as donors, and TM-LacZ mice as recipients. 
Under these conditions, ?-galactosidase serves as a minor histocompatibility 
alloantigen. The following BM chimeric mice were generated: wt ? wt, wt ? 
LacZ and LacZ ? LacZ. All TM-LacZ recipients remained healthy (Figure 
11C), even after repetitive immunization with ?-gal(500-507)-pulsed DC (Figure 
11A). No signs of graft-versus-host-disease were observed. This 
immunization process induced strong CTL expansion in wt ? wt mice (Figure 
11B, 11D). At the same time, expansion of peptide specific CTL was reduced 
in both wt ? LacZ and LacZ ? LacZ recipients.  Taken together, these data 
indicate that antigen expressed on EC alone is sufficient to restore 
alloantigen-specific tolerance in TM-LacZ mice. 
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Figure 11. i.v. immunization of C57BL/6 ?  TM-LacZ bone marrow chimeric mice with ?-
gal(500-507)-pulsed DC.  
(A) Outline of the experimental design: Bone marrow chimeric mice C57BL/6 ? C57BL/6 
(wt?wt), C57BL/6 ? TM-LacZ (wt ?LacZ) and TM-LacZ ? TM-LacZ (LacZ?LacZ) were 
immunized with 5 ? 105 ?-gal(500-507)-pulsed DC. (B) On day 14, splenocytes were isolated for 
intracellular cytokine staining of IFN?. Data shown mean ± SEM of peptide-specific CD8+ T 
cells in spleen from two independent experiments with similar outcome. (C) The body weight 
loss or gain of mice in representative groups within two weeks. Shown is mean ± SEM. (D) 
Intracellular cytokine staining of individual mice was pooled from two experiments. Red lines 
represent median values. 
 
 
3.1.3 Endothelial ?-galactosidase as a “foreign” or “third party” 
antigen (adoptive transfer of effector CTL or primed splenocytes)  
To directly expose EC to effector CTL, 106 or 107 ?-gal-specific CTL that were 
expanded and tested in vitro (Figure 5), were injected i.v. to wt or TM-LacZ 
mice, followed by repetitive immunization with peptide-pulsed DC (Figure 
12A). No peptide-specific CD8 T cells were detectable in TM-LacZ mice 
regardless of the number of effector CTL that was injected (Figure 12B). No 
obvious health problems or body weight change was observed in the 
recipients (Figure 12C). These results indicate that adoptively transferred 
peptide-specific effector CD8 T cells fail to precipitate disease, and obviously 
do not home to the spleen, even after the injection of 107 CTL (corresponding 
to 10% of average total splenocyte number).  
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Figure 12. i.v. immunization of TM-LacZ mice with ?-gal(500-507)-pulsed DC after adoptive 
transfer of ?-gal specific effector CTL. 
(A) Outline of the experimental design: 10
6 
or 10 ? 106 cultured effector CTL were adoptively 
transferred i.v. into TM-LacZ and wt mice. In order to activate adopted T cells, mice were 
immunized with 5 ? 105 ?-gal(500-507)-pulsed DC intravenously on day 0, 1 and 2, repetitively. 
(B) Two weeks after immunization, splenocytes of recipient mice were analyzed for 
intracellular cellular cytokine staining. Each symbol represents an individual mouse, and red 
lines represent median values. (C) Changes in the body weight of mice in representative 
groups (pooled data) within two weeks.  
 
 
It was recently study shown that fully-differentiated effector CTL cells were 
less effective for adoptive transfer in an auti-tumor immune-therapy model 62. 
Therefore instead of effector CTL, primed-effector splenocytes were used for 
adoptive transfer into the mice, followed by immunization of peptide-pulsed 
DC. Wt mice were able to mount a detectable peptide-specific immune 
response, but in TM-LacZ mice, a ?-gal(500-507)-specific CTL were not detected 
in the spleen (Figure 13B, 13D). Again, as for the previous experiments, no 
significant body weight change indicating general disease was observed 
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(Figure 13C). These experiments demonstrate that overt CTL mediated 
vascular injury cannot be induced by adoptive transfer of mature effector CTL 
or primed splenocytes into TM-LacZ mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. i.v. immunization of TM-LacZ mice with ?-gal(500-507)-pulsed DC after adoptive 
transfer of ?-gal specific splenocytes. 
(A) Outline of the experimental design: 25 ? 106 splenocytes (containing about 4 ? 105 
peptide specific CTL) from ?-gal(500-507) immunized wt mice were adoptively transferred to TM-
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LacZ and wt mice. On day 1, 2, 3, the mice were immunized with 5 ? 105 ?-gal(500-507)-pulsed 
DC. Mice were treated with Poly(I:C) or PBS i.p. one day before splenocytes adoptive 
transfer. (B) On day 14, splenocytes of recipient mice were isolated for intracellular cellular 
cytokine staining. Data is the mean (± SEM of two independent experiments with similar 
outcome). (C) The body weight loss or gain of mice in representative groups within two 
weeks. (D) Intracellular cytokine staining of individual mice was pool from all experiments. 
Red lines represent median values. 
 
 
3.1.4 Route of immunization affects the number of ?-gal(500-507) 
specific CD8 T cells in TM-LacZ mice 
We next tested whether the route of DC administration is important for the 
outcome of immunization. Wild type and TM-LacZ mice were immunized 
intravenously (i.v.), subcutaneously (s.c.) or intraperitoneally (i.p.) with ?-
gal(500-507)-pulsed DC. Subcutaneous immunization increased the number of 
peptide specific CTL both in wt and TM-LacZ mice, but no significant 
increasing in both mice after i.p. immunization (Figure 14A, 14B). When ?-
gal(500-507)-primed splenocytes were adoptively transferred before 
immunization, the peptide-specific CTL population was more pronounced 
raising to an average of 1% of the CD8+ T cells from spleen in TM-LacZ mice 
(Figure 14C, 14D). Under these conditions, the difference between wt and 
TM-LacZ mice disappeared. These results suggested that subcutaneous 
immunization with peptide-pulsed DC combined with primed splenocytes 
adoptive transfer was able to overcome tolerance of ?-galactosidase and 
enabled unrestricted expansion of peptide-specific CTL in TM-LacZ mice. 
However, no antigen-specific, CTL-mediated vascular injury was observed 
even when anti-?-gal CD8+ T cells were detectable in TM-LacZ mice (Figure 
14E). This suggests that ?-galactosidase antigen expression by endothelial 
cells is not recognized or ignored by peptide-specific CTL.  
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Figure 14. Route of immunization affects the level of peptide-specific CD8
+ 
splenocytes. 
(A) TM-LacZ and wt mice were immunized i.v., s.c. or i.p. with 5 ? 105 ?-gal(500-507)-pulsed DC, 
repetitively. As control, wt mice were immunized i.v. with un-pulsed DC. Two weeks after 
immunization, splenocytes from immunized mice were tested for peptide specific CTL. Values 
represent mean (± SEM of two independent experiments with similar outcome). (B) 
Intracellular cytokine staining of individual mice from (A). Red lines represent median values. 
(C) TM-LacZ and wt mice received 25 ? 106 ?-gal(500-507)-primed splenocytes. On day 1, 2, 3, 
the mice were immunized either i.v. or s.c. with 5 ? 105 ?-gal(500-507)-pulsed DC. On day 14, 
splenocytes of recipient mice were isolated for intracellular cytokine staining. Values 
represent mean (± SEM of three independent experiments with similar outcome). (D) 
Intracellular cytokine staining of individual mice was pool from (C). Red lines represent 
median values. (E) Changes in the body weight of mice within two weeks after received 25 ? 
10
6
 ?-gal(500-507)-primed splenocytes and DC/?-gal(500-507) immunization. 
 
 
3.1.5 Toll-like receptor activation does not precipitate immune-
mediated injury  
Lang 63 showed that among the various of Toll-like receptor ligands, Poly(I:C) 
was able to transform tissue infiltration by autoreactive CTL into overt 
autoimmune disease. The mechanism was hypothesized to be upregulation of 
MHC class I molecules by IFN?. Therefore mice were immunized 
subcutaneously by peptide-pulsed DC in order to generate CTL; 9 and 11 
days after immunization, mice were treated with poly(I:C) in order to activate 
antigen presenting cells (Figure 15A). Both TM-LacZ mice and wt mice 
remained healthy (Figure 15C). When we examined several organs, we found 
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that 1/4 of mice had signs of liver injury, but this finding was non-specific, i.e. 
independent of antigen expression by endothelial cells (Figure 15D, 15E). 
This finding may be caused by the activation of innate immune cells in the 
liver through poly(I:C).  
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Figure 15. Subcutaneous immunization of wt, TM-LacZ mice with ?-gal(500-507)-pulsed 
DC.  
(A) Outline of the experimental design: wt, TM-LacZ and Rosa26-LacZ mice were immunized 
s.c. with 5 ? 105 ?-gal(500-507) peptide pulsed bone-marrow derived DC on day 0, 1 and 2, 
repetitively, and treated with Poly(I:C) i.p. on day 11 and 12. (B) Two weeks after 
immunization, splenocytes from immunized mice were tested for peptide-specific CD8
+
 T cells 
by intracellular production of IFN? upon in vitro stimulation with or without ?-gal(500-507) peptide. 
Each symbol represents an individual mouse. Red lines represent median values. (C) The 
body weight loss or gain of mice in representative groups within two weeks. (D) H&E staining 
of lung, liver, kidney and heart. Black star shows abnormal. (E) Mean inflammatory infiltrates 
severity scores in lung, kidney, liver and heart of recipients. Each symbol represents an 
individual mouse. Mean inflammatory infiltrates severity scores were calculated as following: 
(score of lung + score of liver + score of kidney + score of heart) / 4. Red lines represent 
median values. Score definitions see Figure 9. 
 
 
Similar outcome was observed, when we treated mice with Poly(I:C) before 
peptide-primed splenocytes adoptive transfer and peptide-pulsed DC 
immunization (Figure 13A). No difference of peptide-specific CD8+ T cells 
expansion in spleen was detected between Poly(I:C) and PBS treated wild 
type and TM-LacZ mice (Figure 13B, 13D). During the whole experimental 
process, no significant body weight change corresponding to general disease 
was observed (Figure 13C), although administration of Poly(I:C) to the mice 
resulted in substantial production of IFN? in circulating blood (Figure 7) and 
precipitated liver disease in some of the mice. 
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3.1.6 Antigen-specific graft versus host disease in Rosa26-LacZ 
mice with ubiquitous expression of ?-galactosidase  
To test whether the ubiquitous antigen expression on target cells would 
precipitate GVHD like disease in this animal model, Rosa26-LacZ mice, which 
express ?-galactosidase ubiquitously in most tissues of the adult mouse were 
used as BM recipients. BM chimeric mice (wt ? wt and wt ? Rosa) were 
repetitively immunized with 5 ? 105 ?-gal(500-507)-pulsed DC in different 
administration route, meanwhile treated with Poly(I:C) i.p. at different time 
points (Figure 16A). During this long lasting experiment, 100% of wt, but only 
66.7% of Rosa26-LacZ mice survived (Figure 16B). Two Rosa26-LacZ mice 
were sacrificed 10 weeks after s.c. immunization with 5 ? 105 ?-gal(500-507)-
pulsed DC combine poly(I:C) treatment, because of signs of GVHD. The mice 
developed inflammatory ulcerative skin disease around the s.c. injection site 
(Figure 16C). No other organ injury was observed. Two weeks after the last 
immunization, when the mice were sacrificed, about 20 times more peptide 
specific CD8+ T cell were detected in wild type spleen (5.8%) than in Rosa26-
LacZ spleen (0.3%) (Figure 16D). Organ immunohistochemical staining 
showed that this experiment setting induced chronic fibrotic inflammation in 
lung, liver and kidney, but not in heart of all recipients (Figure 16F). There was 
a trend to more sever tissue injury in Rosa26-LacZ mice, but this was not 
significantly different between wt and Rosa26-LacZ (Figure 16G). The only 
sign suggesting antigen specific response is body weight change. During the 
nine months, the weight of wt ? wt mice increased by 15 ± 4 %, whereas in 
wt ? Rosa mice the weight remained stable (Figure 16E). The results of this 
long term experiment suggest that a certain level of antigen dependent tissue 
injury and disease can be observed in wt ? Rosa mice, but this is not 
reflected by the number of peptide specific CD8 T cells in spleen. 
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Figure 16. Organ injury occurred in chimeric mice after long-term treatment.  
(A) Outline of the experimental design: Bone marrow chimeric mice C57BL/6 ? C57BL/6 (wt 
? wt) and C57BL/6 ? Rosa26 (wt ? Rosa) were immunized with 5 ? 105 ?-gal(500-507)-pulsed 
DC in different administration route, meanwhile treated with Poly(I:C) i.p. at different time 
points. (B) Survival curve of mice after bone-marrow transplantation. (C) Mice were killed on 
day 152 showed GVHD-like skin lesion on the ears and upper back. L and R indicate left side 
and right side of mouse. Black stars show subcutaneous injection site. (D) On day 14 after 
last immunization, splenocytes of recipient mice were isolated for intracellular cellular 
cytokine staining. (E) Changes in body weight of mice in representative groups within nine 
months. (F) Lung, liver, kidney and heart of chimeric mice and normal Rosa26-LacZ were 
analyzed by H&E staining. (G) Mean inflammatory infiltrates severity scores in lung, kidney, 
liver and heart of chimeric mice and normal mice after immunization and Poly(I:C) treatment. 
Each symbol represents an individual mouse. Red lines represent median values. 
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3.2 Lung inflammatory infiltrates (LII) after intravenous 
injection of leucocytes 
 
3.2.1. Intravenous injection of DC and splenocytes, but not BM 
cells induce lung inflammatory infiltrates 
The systematic histological examination of various organs (liver, lung, kidney 
and heart) for signs of immune mediated injury revealed an unexpected 
finding: after intravenous injection of leucocyte suspensions, we found 
consistent and reproducible lung inflammatory infiltrates (LII) of variable 
severity.  
In the second part of my thesis, I investigated the pathogenesis of these LII, 
which did not severely affect the mice but histologically resembled 
perivasculitis. This perivascular inflammation was limited to the lung, and not 
observed in other organs.  
 
We initially discovered the inflammatory infiltrates in lung two weeks after 
immunization with 0.5 ? 106 ?-gal(500-507) peptide pulsed DC. In all recipient 
mice variable degrees of lung inflammatory infiltrates were detected but 
kidneys appeared normal at the same time (Figure 17A, 17B). To quantify the 
histological alteration in the lung, a scoring system ranging from 0 to 2 was 
established (see method and Figure 9). Similar LII were also observed two 
weeks after intravenous adoptive transfer of 25 ? 106 ?-gal(500-507)-primed 
splenocytes in mice (Figure 18A, 18B). The combined injection of DC and 
splenocytes, i.e. 25 ? 106 ?-gal(500-507)-primed splenocytes intravenously 
injected on day 0, and 0.5 ? 106 ?-gal(500-507)-pulsed DCs for i.v. immunization 
on day 1, 2 and 3, both wild type and TM-LacZ mice developed the most 
severe inflammatory infiltrates of the lungs. The LII in combination-injected 
recipients were scored as 2 (Figure 19B), and in simple DC and splenocytes 
injected recipients were scored as 1, respectively. This infiltrates were 
predominantly localized around blood vessels. Giant cells were observed in 
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some lesion areas, but no pathological findings were observed in other organs 
of these mice (Figure 19A, 19B). The giant cells suggested a foreign body 
reaction to be involved in the phenomenon. However, when bone marrow 
cells were prepared essentially with the same reagents as splenocyte 
suspension and used for injection, no infiltrate was observed (Figure 18A). 
Taken together, we found that DC or splenocytes i.v. injection, but not BM,  
are sufficient to induce LII. Splenocytes combined with DC exerted an additive 
effect on the inflammatory infiltrates.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Intravenous injection of DCs induces lung inflammatory infiltrates in mice.   
0.5 ? 106 ?-gal(500-507)-pulsed DCs were adoptively transferred i.v. into wt and TM-LacZ mice 
on day 0, 1and 2, and organs were analyzed on day 14 (see Figures 10A). (A) H&E stained 
section of lung and kidney from wt and TM-LacZ mice. (B) Inflammatory infiltrates severity 
scores in lung and kidney from wt (open symbols) and TM-LacZ (close symbols) mice after 
immunization.  
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Figure 18. Intravenous injection of splenocytes and DC, but not BM cells induces lung 
inflammatory infiltrates in mice.   
(A) PBS, 25 ? 106 splenocytes, 10 ? 106 bone marrow cells or 0.5 ? 106 cultured DC were 
adoptively transferred i.v. into the mice, and lungs were analyzed on day 14. Red lines 
represent median values. (B) see next page. Immunohistochemical analysis of lung 
inflammatory infiltrates for CD4 (helper T cells), CD8 (cytotoxic T cells), F4/80 (macrophages) 
and CD11c (dendritic cells) positive cells after i.v. injection of splenocytes, bone marrow and 
DC.  
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Figure 19. Intravenous injection of splenocytes and DCs induce the most sever lung 
inflammatory infiltrates in mice.   
25 ? 106 ?-gal(500-507)-primed splenocytes on day 0 and 0.5 ? 106 ?-gal(500-507)-pulsed DCs 
were adoptively transferred i.v. into the mice on day 1, 2 and 3, and organs were analyzes on 
day 14 (see Figure 13A). (A) H&E stained section of lung and kidney from wt and TM-LacZ 
mice. (B) Inflammatory infiltrates severity scores in lung and kidney of wt (open symbols) and 
TM-LacZ (close symbols) mice after cells adoptive transfer. Red lines represent median 
values. (C) see next page. Immunohistochemistry analysis of lung inflammatory infiltrates for 
CD4, CD8, F4/80 and CD11c (right panel). PBS-treated lung (middle panel) was used as 
control. Spleen (left panel for CD4, CD8 and F4/80) and cultured DC (left panel for CD11c) 
were stained as control. Yellow arrowheads indicate giant cells. 
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3.2.2. CD4, CD8 and CD11c+ cells are involved in the pathogenesis 
of lung inflammatory infiltrates 
The three cell suspensions (splenocytes, DC and BM) were further 
characterized by FACS (Table 2). Splenocytes contain about 25.3 ± 1.2 % 
CD4+, 11.5 ± 1.2 % CD8+, about 2.4 ± 0.7 % macrophages (F4/80+) and 5.3 ± 
1.2 % CD11c+ cells under the gate of leucocytes (Figure 20A); cultured 
dendritic cells contain 73.2 ± 3.4% CD11c positive, nearly no CD4, CD8, nor 
macrophages (Figure 20B); BM contains only about 8.9 ± 1.2 % CD11c+, 4.8 
± 3 % F4/80+ and 1.3 ± 0.1% CD4+ and 1.1 ± 0.2 % CD8+ (Figure 20C). This 
suggests that CD11c+ are sufficient for the induction of LII and macrophage 
may not be involved in the pathogenesis.  
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Figure 20. Comparison of leukocyte component in splenocytes, DC and BM for 
adoptive transfer. 
C57BL/6-Ly5.1 (A) splenocytes, (B) DC or (C) BM were adoptively transferred intravenously 
to the recipients. The donor cells were analyzed by FACS with same antibodies as used for 
IHC against CD4, CD8, F4/80, CD11c. Data shown mean ± SEM.  
 
 
We wished to test the role of CD4 and CD8 T cells in the pathogenesis of LII. 
CD4 and CD8 T cells were enriched from splenocytes using magnetic beads 
isolation. The purity of CD4+ and CD8+ T cell population were 82.8 ± 2.3 % 
and 86.6 ± 1.9 %, respectively. There were still 1.1 ± 0.3 % and 1.8 ± 0.9 % of 
macrophages, 0.7 ± 0.5 % and 1.1 ± 0.9 % of CD11c+ cells in purified CD4 
and CD8 cell population, respectively (Table 2).  
 
 
Table2. Comparison of leukocyte component in splenocytes, DC, BM, purified CD4 and 
purified CD8 using for adoptive transfer 
 
CD4 CD8 F4/80 CD11c
splenocytes 25.3±1.2 11.5±1.2 2.4±0.7 5.3±1.2
DC 0±0 0±1 0.4±0.4 73.2±3.4
BM 1.3±0.1 1.1±0.2 4.8±3.0 8.9±1.2
purified CD4 82.8±2.3 7.0±0.1 1.1±0.3 0.7±0.5
purified CD8 0.2±0.1 86.6±1.9 1.8±0.9 1.1±0.9  
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However, intravenously injected CD4+ (Figure 21B, 21G) or CD8+ T cells 
(Figure 21C, 21G) alone did not elicit inflammatory infiltrates in lung, whereas, 
CD4+ and CD8+ T cells injected as combined population to the mice (Figure 
21D, 21G) precipitated strong inflammatory infiltrates. No pathological findings 
were observed when PBS or culture supernatant was injected into normal 
mice (Figure 22E, 22F, 21G). This analysis shows that the cooperation 
between CD4 and CD8 T cell is important to elicit inflammatory infiltrates in 
lung. It also further excludes that simple foreign body reaction is the major 
pathogenic event. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. CD4 or CD8 alone dose not induce lung inflammatory infiltrates. 
HE staining of lung after received different cell population (A) 25 ? 106 splenocytes,  (B) 4.5 
? 106 purified CD4, (C) 3 ? 106 purified CD8, (D) 2.5 ? 106 purified CD4 and CD8, (E) PBS, 
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(F) without injection. (G) Inflammatory infiltrates severity scores in lung of all recipients. Red 
lines represent median values. 
 
 
3.2.3. Route of administration affects the lung inflammatory 
infiltrates  
Since inflammatory infiltrates were found exclusively in the lung, we next 
tested the role of the administration route. When we looked for LII two weeks 
after i.v., s.c., or i.p. injection of DC, only i.v. injected DC induced lung 
inflammatory infiltrates in mice, whereas no inflammatory infiltrates occurred 
in s.c. and i.p. injected recipients (Figure 22).  Both TM-LacZ mice, that 
express high amount of ?-galactosidase in the lung (Figure 2C, 2D), and wt 
mice developed similar inflammatory foci (Figure 22, 17B). These results 
demonstrated that intravenous injection and not antigen expression was 
essential for the development of lung inflammatory infiltrates in mice. 
Particularly, antigen presentation by endothelial cells was not involved in 
pathogenesis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Route of administration induce lung inflammatory infiltrates in mice. 
0.5 ? 106 ?-gal(500-507)-pulsed DC were adoptively transferred i.v., s.c. or i.p. into the mice and 
lungs were analyzed on day 14. Inflammatory infiltrates severity scores of wt (open symbols) 
and TM-LacZ (close symbols) mice after adoptive transfer. Red lines represent median 
values. 
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3.2.4. Inflammatory cells showed high proliferation rate in lesion 
area 
Lung inflammatory infiltrates built up in lung over time (Figure 23). There were 
very few infiltrates observed two days after splenocytes injection i.v.. The 
peak of infiltrates occurred two weeks after injection, and persisted for at least 
five weeks. This observation suggests that LII developed by proliferation 
rather than by simple trapping. This hypothesis was confirmed by in vivo BrdU 
labeling! One week before sacrifice, the recipients were fed with BrdU in the 
drinking water. The newly synthesized DNA was detected in the inflammatory 
infiltrates by immunohistochemistry (65 ± 2.5% and 64 ± 1.4% proliferated 
cells in splenocytes recipients and DC recipients, respectively) (Figure 24A, 
24C). In normal lung tissue, as expected, had a low proliferation index and 
only few lung resident cells (4 ± 0.3% and 3.5 ± 0.5% proliferated cells in 
splenocytes recipients and DC recipients, respectively) (Figure 24C) were 
positive for BrdU. This experiment shows that LII developing over time 
contained a large number of proliferating cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Intravenous injection of splenocytes induced persistent lung inflammatory 
infiltrates.   
25 ? 106 ?-gal(500-507)-primed splenocytes were adoptively transferred i.v. into the mice, and 
lungs were analyzed on day 2, 14 and 35. Inflammatory infiltrates severity scores of wt (open 
symbols) and TM-LacZ (close symbols) mice after adoptive transfer. Red lines represent 
median values.  
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3.2.5. Inflammatory cells are the recipient origin 
We next wished to determine whether LII were of donor or of recipient origin. 
To check the origin of inflammatory cells in lung inflammatory infiltrates area, 
C57BL/6-Ly5.1 splenocytes or DC were injected intravenously into C57B/L6-
Ly5.2 recipients. After two weeks, only 1% of CD45.1+ donor cells (Figure 
24A, 24D) were detectable in the lung of the recipient after the injection of 
splenocytes. These cells were scattered throughout the organ. About 3% of 
CD45.1 positive cells were found in the spleen and 0.6% in peripheral blood 
(Figure 24E). After the injection of DC, 0.7% of CD45.1 positive cells were 
found in lung (Figure 24D), only very few in the spleen and in peripheral blood 
(Figure 24E). Again, the majority of cells in the LII were CD45.2 positive, i.e. 
of recipient origin (Figure 24A). This observation suggests that donor 
splenocytes or / and DC injection stimulated focal lung inflammatory cell 
proliferation of recipient cells.  
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Figure 24. Origin and proliferation state of lung inflammatory infiltrates. 
C57BL/6-Ly5.1 splenocytes or DC were adoptively transferred intravenously to the C57BL/6-
Ly5.2 recipients, and the recipient mice were fed with BrdU drinking water for one week 
before sacrificed. Two weeks after adoptive transfer, (A) Immunohistochemistry analysis of 
lung inflammatory infiltrates for CD45.1 (donor leucocytes), CD45.2 (recipient leucocytes), 
CD4, CD8, F4/80, CD11c and BrdU (new synthesized DNA). Non-BrdU fed mouse lung was 
stained as control showed in black frame. Yellow arrowheads indicate CD45.1 cells. (B) 
Mixed Ly5.1 and Ly5.2 splenocytes (upper row for CD45.1 and CD45.2), spleen (middle row 
for CD4, CD8 and F4/80), cultured DC (lower left for CD11c) and BrdU fed mouse intestine 
(lower middle) were stained as control. In black frame shows Rat IgG stained BrdU fed 
mouse intestine. (C) The percentage of BrdU positive stained the cells in LII and in health 
area. (?) indicates in LII area, (?) indicates in health area. (D) The percentage of CD45.1 
positive stained the cells in LII and in health area. (E) PBMC and spleen cells of recipient 
were detected by FACS stained with FITC labelled anti-CD45.1. (F) The percentage of CD4, 
CD8, F4/80 and CD11c positive cells in LII area after various leucocytes i.v. injection. 
Percentage of positive cells / total cells in area was calculated as: positive stained cells in 
lesion area / total cells in lesion area ? 100%. 
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3.2.6. CD11c+ cells were the dominant population within LII  
To further analyze the cellular composition of cells in the area of LII, 10μm 
thick lung cryosections were stained with antibodies specific for helper T cells 
(CD4), cytotoxic T cells (CD8), macrophages (F4/80) and dendritic cells 
(CD11c). CD11c positive cells, macrophages, a few CD4+ cells, but no CD8+ 
cells were found in the infiltrates after splenocytes or / and DC i.v. adoptive 
transfer (Figure 18B, 19C, 24F). Interestingly, the cellular composition in LII 
was similar after DC and splenocytes adoptive transfer, respectively. Few 
resident F4/80 and CD11c positive cells were detectable by 
immunohistochemical staining, but they are scattered in a different pattern of 
distribution in the normal looking lung (Figure 19B, 24F).  
 
 
3.2.7. Endothelial cells were preserved in inflammatory infiltrates 
area 
TM-LacZ mice express ?-galactosidase on endothelial cells and LII formed 
exquisitely around pulmonary blood vessels. To analyze the integrity of blood 
vessel in the centre of LII, the X-gal substrate staining was used to identify the 
EC on TM-LacZ lung section. In 6/62 normal TM-LacZ mice, the X-gal 
substrate staining for examining ?-galactosidase activity was complete 
negative, 7/67 mice was negative in 10-20 % of lung area, due to the 
technical limitation, e.g. 4% PFA perfusion fixation did not completely reach 
every capillary of entire lung resulting the loss of ?-galactosidase activity. We 
observed this in 4 / 31 experimental TM-LacZ mice, as well, the X-gal 
substrate staining for enzymatic ?-galactosidase activity was complete 
negative, even in the unaffected lung area. After intravenous injection of 
various leucocytes into the mice, most inflammatory infiltrates were found 
around endothelial cells of vein (Figure 25B) and artery (Figure 25C) in TM-
LacZ mouse, but the EC themselves were preserved (Figure 25D). Taken 
together, these results showed that the lung inflammatory cells are of recipient 
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origin, mostly CD11c+ and were formed by local proliferation. No substantial 
tissue injury did occur and even vascular EC were mostly preserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Endothelial cells were preserved in inflammatory infiltrates. 
25 ? 106 ?-gal(500-507)-primed splenocytes or 0.5 ? 106 ?-gal(500-507)-pulsed DC or combined 
cells were adoptively transferred i.v. into the mice, and lungs were analyzed on day 14. 10μm 
thick lung cryosections after received 25 ? 106 ?-gal(500-507)-primed splenocytes were stained 
with H&E (A), X-gal (B) and CD11c (C). Upper row is normal lung, middle and lower row 
shows inflammatory infiltrates around vein and artery. Yellow arrowheads indicate endothelial 
cells stained with X-gal. (D) Schematic shows the X-gal staining of lung. Blue circles indicate 
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X-gal stained blood vessels, pink indicate inflammatory infiltrates. (E) Summary of 
endothelium integrity of TM-LacZ mice using X-gal staining.  Frequency of X-gal stained 
blood vessels = number of positive stained blood vessels in inflammatory infiltrates of whole 
lung area / all vessels in inflammatory infiltrates of whole lung area ? 100% = 10 /12 * 100 = 
83.3%. 
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4. Discussion 
 
In this thesis project, I made two important observations: first, despite of 
successful induction of an antigen-specific CTL-response, CTL-mediated 
endothelial injury in a mouse model of endothelial cell-selective antigen 
presentation could not be observed in vivo. Second, intravenous injection of 
splenocytes, dendritic cells, or both, induced reproducibly focal, non-specific 
perivascular lung inflammatory infiltrates containing abundant CD11c+ cells.   
In the following paragraphs these two findings are discussed separately. 
 
Part 1. Endothelial cells as targets of antigen-specific CTL 
 
The major goal of this thesis project was to investigate antigen-specific and 
antigen-dependent endothelial injury mediated by antigen-specific CTL in 
vivo. In order to reach this goal, a mouse model was chosen in which E.coli ?-
galactosidase (LacZ) was expressed under the control of the thrombomodulin 
promoter, i.e. selectively in vascular endothelial cells. In these TM-LacZ mice, 
LacZ expression in the vascular EC was patchy, not uniform. Pulmonary 
blood vessels were uniformly and strongly LacZ positive whereas liver EC 
were virtually LacZ negative. This inherent variability in antigen-expression 
representing an internal control should guarantee the identification of truly 
antigen-specific endothelial injury. Adoptive transfer of ?-gal(500-507)-primed 
wild type splenocytes followed by repetitive subcutaneous immunization of 
TM-LacZ mice with ?-gal(500-507)-pulsed DC was able to break tolerance 
against the autoantigen LacZ in these TM-LacZ mice. In the spleen, on 
average 1 (0.54-1.2)% of total CD8+ T cells were shown to be ?-gal(500-507) 
specific effector cells. This was similar to the result of this immunization 
procedure in wt mice. However, despite of the successful immunization, the 
mice did not develop disease. Body weight was stable over time and at the 
tissue level, microscopic analysis did not reveal antigen specific endothelial 
injury or tissue infiltration by CD8+ T cells. This is surprising since in a similar 
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model, in which the same antigen (LacZ) is expressed under the control of the 
smooth muscle cell actin promoter 69, DC immunization using the same 
peptide was also able to break self-tolerance but lead to CD8+ T cell-mediated 
vasculitis. Furthermore, in various models of antigen-specific, peptide-
dependent, MHC class I restricted immune responses, the number of peptide-
specific CTL in the spleen was accurately reflecting an efficient generation of 
systemically active effector T cells 71,80-82. Our negative result could have 
several explanations. The peptide-specific CTL that were detected after ?-gal 
immunization could be self-reactive low affinity T cells 83 and therefore, the 
amount of ?-gal peptide presented by EC might be too low for efficient target 
cell injury in vivo. However, the cytotoxic potency of the cell lines that 
emerged from these splenocytes after ex vivo expansion was remarkable 
since at an E:T ratio of <10:1 and with peptide concentrations of 10-5 M for 
target cell pulsing still more than 60% specific killing was observed (Figure 
5B). Furthermore, upregulation of antigen-expression in target tissues by 
poly(I:C) treatment did not precipitate endothelial injury (Figure 15B). Finally, 
endothelial cells could present a distinct peptide repertoire and lack the 
immunodominant ?-gal(500-507) peptide among their MHC class I ligands. In fact 
we have previously shown 84 for human EC that SMCY(311-319) derived peptide 
FIDSYICQV was presented at a negligible amount on the cell surface. 
Therefore, SMCY-specific CTL with high potency were unable to recognize 
and eliminate male target EC but were successfully eliminating male B-
lymphoblastoid cells. A recent publication described ignorance of endothelial 
cells by peptide-specific CTL as a mechanism of antigen-specific tolerance in 
another mouse model of endothelial ?-galactosidase expression 57. The Tie2-
LacZ mice express the E.coli protein uniformly in all endothelial cells. In 
addition to the antigen-specific ignorance of endothelial cells, these mice also 
developed antigen-specific tolerance. This peripheral tolerance was shown to 
depend on crosspresentation of LacZ by CD11c+ bone marrow derived cells, 
putatively dendritic cells. We also observed antigen-specific peripheral 
tolerance against LacZ in TM-LacZ mice, but only for intravenous 
immunization. As mentioned in the beginning, subcutaneous immunization 
could easily break tolerance in the TM-LacZ mice and resulted in large 
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numbers of antigen-specific, potent, CD8+ splenocytes. If endothelial cells 
could specifically escape CTL-mediated injury by presenting insufficient 
amounts of antigen, mice which express ?-galactosidase ubiquitously should 
develop GVHD-like disease after the same immunization procedure. In fact, 
Rosa26-LacZ mice, which express E.coli ?-galactosidase in all nucleated 
cells, developed antigen-specific disease with relative weight loss immediately 
after immunization with ?-gal(500-507)-pulsed DC (Figure 16E). Furthermore, 
two of the immunized Rosa mice developed GVHD-like disease 10 weeks 
after immunization. Both Rosa26-LacZ and wt mice had signs of chronic 
tissue inflammation, but the injury score was more severe in the Rosa26-LacZ 
mice. This single, long term experiment demonstrates that antigen-specific, 
chronic GVHD like disease can be induced in mice in which one protein, 
LacZ, serves as a source for minor histocompatibility antigens when this 
protein is expressed ubiquitously in all tissues of the body and when its 
expression is not restricted to the endothelium.   
 
We conclude that in this model of focal, endothelial cell restricted antigen 
expression, vascular injury cannot be induced despite of successful induction 
of an antigen-specific CTL response. This finding may have implications for 
non-cytopathic endothelial infections (e.g. by cytomegalovirus human 
immunodeficiency virus), immune-defense against endothelial neoplasias or 
to understand the phenotype of alloimmune diseases, particularly graft versus 
host disease after MHC matched stem cell transplantation.  
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Part 2. Lung inflammatory infiltrates after intravenous leukocyte 
injection 
 
As an unexpected, novel finding we observed reproducibly perivascular 
inflammatory infiltrates after intravenous injection of various leukocyte 
populations over a broad range of cell counts. 25 x 106 splenocytes, 0.5 x 106 
bone marrow derived dendritic cells, or both together induced focal, 
perivascular proliferation and expansion of mostly CD11c+ cells.  
Interestingly, neither CD4+ cells nor CD8+ cells alone, but the combination of 
the two, were able to precipitate LII. Although some of the most advanced LII 
also contained giant cells resembling foreign body reaction, we had no 
evidence that this was the major pathogenic mechanism. 1) foreign body 
material was not observed in histological preparations, 2) neither CD4+ nor 
CD8+ cell suspensions induced the LII, but the combination of the two, 3) 
bone marrow cells were not sufficient to induce LII and 4) none of the cell 
culture media or washing buffers alone induced LII.  
 
The obvious etiology of this phenomenon is intravenous injection of leukocyte 
suspensions of variable origin and composition. This suggests that it might 
represent a model for a variety of well known, well described lung diseases 
associated with stem cell transplantation (e.g. interstitial pneumonia syndrome 
85), blood transfusions (e.g. transfusion associated lung injury 86) or adoptive 
lymphocyte transfer for fighting leukemia relapses or transplant associated 
viral infections 87.  
 
On the other hand, the predominance of proliferating CD11c+ cells regardless 
of the original cell suspension that was injected is puzzling. This suggests that 
the procedure elicited lung vascular injury and precipitated a common final 
pathway resulting in a uniform repair process eventually leading to granuloma 
formation. The granuloma were of variable severity but vascular endothelium 
within the LII was mostly preserved. Endothelial integrity and absence of 
vessel wall necrosis or erythrocyte extravasation argues against fully 
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developed vasculitis. This is also in accordance with the absence of any 
obvious sign of disease in these mice. Perivascular CD11c+ dendritic cells are 
also an important and predominant leukocyte population in other vascular 
disorders like giant cell arteritis 88.  
 
A strikingly similar finding has recently been reported in mice after intravenous 
injection of FasL-transfected dendritic cells 89. We analyzed FasL expression 
by our bone marrow derived DC and found it to be negative. The common 
ground for the observation by Buoncore and us may not be the injected DC 
but the type of lung endothelial injury induced by the injected cells.  
 
We may have established a novel animal model for an early stage of pauci-
immune or ANCA-associated pulmonary vasculitis. It is highly reproducible 
and due to the persistent nature of the granuloma formation it is suitable for 
further interventions aiming at precipitating bona fide pulmonary vasculitis or 
aiming at resolution of the non-caseating granuloma.  
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6. List of Abbreviations 
 
 
APC    Antigen presenting cell 
BM    Bone marrow 
BMT    Bone marrow transplantation 
BrdU    5-Bromo-2'-deoxyuridine   
CTL    Cytotoxic T lymphocytes 
DAB    3,3'-Diaminobenzidine 
DC    Dendritic cell 
DMSO   Dimethyl sulfoxide 
DNase   Deoxyribonuclease 
EC    Endothelial cell 
ELISA    Enzyme-Linked ImmunoSorbent Assay 
FACS    Fluorescence activated cell sorting 
FCS    Fetal calf serum 
FDG    Fluorescein di-D-galactopyranoside 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
gPBS    Glucose containing phosphate-buffered saline  
GVHD    Graft versus host disease 
HBSS    Hank's Buffered Salt Solution 
HRP    Horseradish peroxidase 
HUVEC   Human umbilical vein endothelial cells 
IFN?    Interferon alpha 
IFN?    Interferon gamma 
IHC    Immunohistochemistry 
IL-2    Interleukin 2 
IL-4    Interleukin 4 
IPS    Idiopathic pneumonia syndrome 
LII    Lung inflammatory infiltrates 
MHC I    Major histocompatibility complex class I 
MHC II   Major histocompatibility complex class II 
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MPA    Microscopic polyangiitis 
OVA    Chicken ovalbumin 
PBMC    Peripheral blood mononuclear cells 
PBS    Phosphate-buffered saline 
PI    Propidium iodide 
PMA    Phorphol myristate acetate  
poly(I:C)   Polyinosinic–polycytidylic acid potassium salt  
RT    room temperature 
TCR    T cell receptor 
TM    Thrombomodulin 
TNF?    Tumor necrosis factor alpha 
X-gal    5-Bromo-4-Chloro-3-Indoyl-D-Galactopyranoside 
WG    Wegener’s granulomatosis 
wt    wild type 
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